Drug Profile
Research programme: peptide-based therapeutics - PYC Therapeutics/Johnson & Johnson Research
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Johnson & Johnson; Phylogica
- Class Peptide fragments
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in Australia
- 21 Apr 2010 Preclinica development is ongoing in Australia
- 12 Jul 2006 Preclinical trials in Undefined in Australia (unspecified route)